Table 1 Main information extracted from included studies
From: Effect of nanoparticles on gouty arthritis: a systematic review and meta-analysis
Study | Year | Animal species | Gender | Quantity | Weight(g) | Group | Intervention | Dosage | Method of administration | Control group | Dosage | Model group | Measured outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kiyani MM; Butt MA | 2021 | BALB/c mice | F; M | 36 | 25–30 | 6 | CuO-NPs | 5, 10, or 20 ppm | oral | Allopurinol | 50 mg/kg | MSU | Histopathology |
Wang S | 2019 | SD rats | M | 48 | 200 ± 10 | 6 | AFIC-CDs | 2, 4, or 8 mg/kg | i.p. | Allopurinol | 5 mg/kg | MSU | Uric acid levels serum; The swelling degree of joints |
Kiyani MM; Moghul NB | 2021 | BALB/c mice | F; M | 42 | 25–30 | 7 | FeO-NPs | 5, 10, or 20 ppm | oral | Allopurinol | 50,100 mg/kg | MSU | Renal Function Test; Liver Function Test; Lipid Profile; Histopathology |
Liu Y | 2020 | SD rats | M | 40 | 180–220 | 5 | GsRb1; nano-GsRb1 | 80 mg/kg | oral | IN | 5 mg/kg | MSU | The swelling degree of joints; Histopathology |
Kiyani MM; Butt MA | 2019 | BALB/c mice | F; M | 140 | 25 ± 10 | 7 | ZnO-NPs | 5, 10, or 20 ppm | oral | Allopurinol | 50 mg/kg | NPs control; MSU | Renal function test; Liver function test; Lipid profile; Blood count; Histopathology |
Kiyani MM; Sohail MF | 2019 | BALB/c mice | F; M | 36 | 25–30 | 6 | T-NPs | 5, 10, or 20 ppm | oral | Allopurinol | 50 mg/kg | MSU | Liver function test; Lipid profile; Renal function test; Blood count; Histopathology |
Kiyani MM; Rehman H | 2020 | BALB/c mice | F; M | 48 | 25–30 | 8 | CuO-NPs | 5, 10, or 20 ppm | oral | Allopurinol | 50,100 mg/kg | MSU; CuSO4 40 mg/kg | Renal function test; Liver function test; Blood count; Lipid profile; Uric acid levels serum; The swelling degree of joints |
Wang X | 2019 | SD rats | M | 36 | 190–210 | 6 | PLR-CDs | 1, 2, or 4 mg/kg | oral | Allopurinol | 5 mg/kg | OXO | The swelling degree of joints; Histopathology |
Hao Y | 2019 | ICR mice | M | 35 | 20–22 | 7 | The uricase& HRP-CaHPO4 @HA MN | - | IM | The HA MN (IM); The uricase (I.v.); The uricase (s.c.); The uricase-CaHPO4@HA MN (IM) | 1U/kg | OXO | Uric acid level serum; Histopathology; Blood count |
Zhang J | 2021 | SD rats | M | 30 | - | 5 | IK-NPs | 0.54 μmol/kg | s.c. | IN | 2 mg/kg | MSU | The swelling degree of joints; Histopathology |